167 related articles for article (PubMed ID: 16887429)
1. Early bisphosphonate treatment in infants with severe osteogenesis imperfecta.
Antoniazzi F; Zamboni G; Lauriola S; Donadi L; Adami S; Tatò L
J Pediatr; 2006 Aug; 149(2):174-9. PubMed ID: 16887429
[TBL] [Abstract][Full Text] [Related]
2. Alendronate treatment in children with osteogenesis imperfecta.
Akcay T; Turan S; Guran T; Bereket A
Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
[TBL] [Abstract][Full Text] [Related]
3. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
DiMeglio LA; Ford L; McClintock C; Peacock M
Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
[TBL] [Abstract][Full Text] [Related]
4. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
[TBL] [Abstract][Full Text] [Related]
5. Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta.
Aström E; Jorulf H; Söderhäll S
Arch Dis Child; 2007 Apr; 92(4):332-8. PubMed ID: 17114205
[TBL] [Abstract][Full Text] [Related]
6. Vertebral fracture assessment (VFA) for monitoring vertebral reshaping in children and adolescents with osteogenesis imperfecta treated with intravenous neridronate.
Diacinti D; Pisani D; Cipriani C; Celli M; Zambrano A; Diacinti D; Kripa E; Iannacone A; Colangelo L; Nieddu L; Pepe J; Minisola S
Bone; 2021 Feb; 143():115608. PubMed ID: 32829035
[TBL] [Abstract][Full Text] [Related]
7. New trends in the treatment of osteogenesis imperfecta type III - own experience.
Jakubowska-Pietkiewicz E; Chlebna-Sokół D
Ortop Traumatol Rehabil; 2008; 10(6):593-601. PubMed ID: 19153548
[TBL] [Abstract][Full Text] [Related]
8. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome.
Munns CF; Rauch F; Travers R; Glorieux FH
J Bone Miner Res; 2005 Jul; 20(7):1235-43. PubMed ID: 15940378
[TBL] [Abstract][Full Text] [Related]
9. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment.
Land C; Rauch F; Munns CF; Sahebjam S; Glorieux FH
Bone; 2006 Oct; 39(4):901-6. PubMed ID: 16730480
[TBL] [Abstract][Full Text] [Related]
10. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
Gatti D; Antoniazzi F; Prizzi R; Braga V; Rossini M; Tatò L; Viapiana O; Adami S
J Bone Miner Res; 2005 May; 20(5):758-63. PubMed ID: 15824848
[TBL] [Abstract][Full Text] [Related]
11. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
12. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Glorieux FH; Bishop NJ; Plotkin H; Chabot G; Lanoue G; Travers R
N Engl J Med; 1998 Oct; 339(14):947-52. PubMed ID: 9753709
[TBL] [Abstract][Full Text] [Related]
13. Intravenous neridronate in adults with osteogenesis imperfecta.
Adami S; Gatti D; Colapietro F; Fracassi E; Braga V; Rossini M; Tatò L
J Bone Miner Res; 2003 Jan; 18(1):126-30. PubMed ID: 12510813
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis.
Antoniazzi F; Bertoldo F; Mottes M; Valli M; Sirpresi S; Zamboni G; Valentini R; Tató L
J Pediatr; 1996 Sep; 129(3):432-9. PubMed ID: 8804334
[TBL] [Abstract][Full Text] [Related]
15. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
[TBL] [Abstract][Full Text] [Related]
16. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age.
Plotkin H; Rauch F; Bishop NJ; Montpetit K; Ruck-Gibis J; Travers R; Glorieux FH
J Clin Endocrinol Metab; 2000 May; 85(5):1846-50. PubMed ID: 10843163
[TBL] [Abstract][Full Text] [Related]
17. Growth of infants with osteogenesis imperfecta treated with bisphosphonate.
Hasegawa K; Inoue M; Seino Y; Morishima T; Tanaka H
Pediatr Int; 2009 Feb; 51(1):54-8. PubMed ID: 19371278
[TBL] [Abstract][Full Text] [Related]
18. Long-term Effects of Neridronate in Adults with Osteogenesis Imperfecta: An Observational Three-Year Italian Study.
Viapiana O; Idolazzi L; Fassio A; Orsolini G; Rossini M; Adami G; Bertoldo F; Gatti D
Calcif Tissue Int; 2017 Apr; 100(4):341-347. PubMed ID: 28130572
[TBL] [Abstract][Full Text] [Related]
19. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen.
Marini JC; Hopkins E; Glorieux FH; Chrousos GP; Reynolds JC; Gundberg CM; Reing CM
J Bone Miner Res; 2003 Feb; 18(2):237-43. PubMed ID: 12568401
[TBL] [Abstract][Full Text] [Related]
20. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age.
Alcausin MB; Briody J; Pacey V; Ault J; McQuade M; Bridge C; Engelbert RH; Sillence DO; Munns CF
Horm Res Paediatr; 2013; 79(6):333-40. PubMed ID: 23735642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]